Список литературы

1. World Health Organization Classification of Tumours of the Haematopoetic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al. IARS Press: Lyon 2008.

2. Treatment of multiple myeloma and relation disorders. Ed. Rajkumar SV and Kyle RA. Cambridge University Press, 2009.

3. Jemal A, Mirray T, Ward E, et al. Cancer Statistics 2005. CA Cancer J Clin. 2005; 55: 10 - 30

4. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's Macroglobulinemia: consensus panel recommendations from Second International Workshop on Waldenstrom"s Macroglobulinemia. Semin Oncol. 2003; 30: 110 - 115

5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Waldenstrom's MacrogobylinemiaLymphoplasmacytic Lymphoma. Version 2.2016 NCCN.org.

6. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Makroglobulinemia. Semin Oncol. 2003; 30: 116 - 120

7. Treon SP, Merlini G, Morra E, et al. Report from Sixth International Workshop on Waldenstrom"s Macroglobulinemia. Clin Lymph Myeloma Leukemia. 2011; 11: 69 - 73

8. Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009; 2(2): 121 - 136

9. Varghese AM, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenstrom"s Macroglobulinemia. Clin Lymph Myeloma Leukemia. 2009; 9: 53 - 55

10. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom Macroglobulinemia. Blood. 2009; 113(18): 4163 - 4170

11. Kyle RA, Greip PR, Gertz MA, et al. Waldenstrom"s Macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000; 108: 737 - 742

12. Treon SP. How I treat Waldenstrom Macroglobulinemia. Blood. 2009; 114: 2375 - 2385

13. Johnson SA, Birchall J, Luckie C, et al. Guielinesonthe management of Waldenstrom Macroglobulinemia. Br J Haematol. 2006; 132: 683 - 697

14. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al. Predictive factors for response to rituximab in Waldenstrom's Macroglobulinemia. Clin Lymphoma. 2005; 5: 270 - 272

15. Treon SP, Ioakimi L, Soumerai JD, et al. Primaly therapy of Waldenstrom Macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009; 27: 3830 - 3835

16. Chen C, Kouroukis CT, White D, et al. Bortezomib is active in patiens with untreated or relapsed Waldenstrom's Macroglobulinemia: a phase II study of the Nationale Cancer Institute of Canada Clinical Trial Group. J Clin Oncol. 2007; 25: 1570 - 1575

17. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol. 2010; 85: 670 - 674

18. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom Macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007; 25: 3344 - 3349

19. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2009; 9: 62 - 66

20. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response and longer time to treatment failure in patients with 20 lymphoplasmacytic lymphoma: results of randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009; 23: 153 - 161

21. Leleu XP, Manning R, Soumerai JD, et al. Increase incidence of disease transformation and development of MDS/AML in Waldenstrom's Macroglobulinemia patients treated with nucleoside analogues. Proc Am Soc Clin Oncol. 2007; 25: 445s.

22. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009; 25: 120 - 126

23. Leblond V. Role of purine analogs in front-line treatment of Waldenstrom's Macroglobulinemia. Haematol. 2007; 92 (s2): 85

24. Thomas SK, Delasalle KB, Gavino M, et al. 2-CDA-cyclophosphamide +/- rituximab for symptomatic Waldenstrom's Macroglobulinemia. Haematol. 2007 (Supplement); 92: PO-1227

25. Myeloma: Biology and management. Second Edition. Ed. Malpas JS, Bergsagel DE, Kyle RA, Anderson CA. SAUDERS 2004

26. Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab patients with Waldenstrom Macroglobulinemia who respond to a rituximab-containing regimen. Br J Haematol. 2011; 154: 357 - 362

27. Treon SP, Branaham AR, Iokimidis L, et al. Long-term outcomes to fludarabin and rituximab in Waldenstrom Macroglobulinemia. Blood. 2009; 113: 3673 - 2378

28. Rummel MJ, Von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the firstline treatment of patients with follicular, indolent and mantle cell lymphomas: result of a randomized phase III study of the StudyGroup Indolent Lymphomas (Stil). Blood. 2008; 112: Abstract 2596.

29. Rummel MJ, Von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with Waldenstrom s Macroglobulinemia: first interim result of a randomized phase III study of the Study Group Indolent Lymphomas (Stil). Proceeding of the 5th International Workshop on Waldenstrom's Macroglobulinemia; Stockholm, Sweden 2008; Abstract 139.

30. Rummel MJ, Niederle N., Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle cell lymphomas: an open-label, multicentre, randomized, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-10.

31. Treon SP, Hanzis C, Tripsas S, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma Leukemia. 2011; 11: 133-5

32. Treon SP, Tripsas S, Meid K, et al. Ibrutinib in Previously Treated Macroglobulinemia. N Engl J Med. 2015; 372: 1430-40